<DOC>
	<DOC>NCT01753193</DOC>
	<brief_summary>The purpose of this study is to evaluate the long-term safety of MEDI-546 in adults with moderate to severe active systemic lupus erythematosus</brief_summary>
	<brief_title>An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults</brief_title>
	<detailed_description>This is an open-label extension study to evaluate long-term safety and tolerability of intravenous (IV) MEDI-546 in adult subjects with moderately-to-severely active systemic lupus erythematosus (SLE). Subjects must have completed the qualifying Phase 2 study and meet this study criteria in order to be eligible.</detailed_description>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Must be willing to use 2 methods of effective contraception Must have venous access Must be willing to forego participation in other clinical trials for SLE. Any concurrent condition that in the opinion of the investigator would interfere with the evaluation of the investigational product Major surgery within 8 weeks before signing ICF Elective major surgery planned during the study period Concomitant Medications within the last 12 weeks: Azathioprine &gt; 200 mg/day, Mycophenolate mofetil/mycophenolic acid &gt; 2.0 g/day, Oral, SC, or intramuscular methotrexate &gt; 25 mg/week A live or attenuated vaccine within 4 weeks of signing the ICF Bacillus of Calmette and Gu√©rin (BCG) vaccine within 1 year of ICF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
</DOC>